Crosstalk between PI3 Kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK pathways downstream PDGF receptor

Cellular Physiology and Biochemistry

Volumn 31, Issue 6, 2013, Pages 905-913

  Niba, Emma Tabe Eko ^a   Nagaya, Hisao ^a   Kanno, Takeshi ^a   Tsuchiya, Ayako ^a   Gotoh, Akinobu ^a   Tabata, Chiharu ^a   Kuribayashi, Kohzo ^b   Nakano, Takashi ^a   Nishizaki, Tomoyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b ASAHI UNIVERSITY   (Japan)

Author keywords

Akt; Crosstalk; ERK; PDGF receptor; Rac1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAC1 PROTEIN; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; WESTERN BLOTTING; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; MESOTHELIOMA CELL LINE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84879487865     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350108     Document Type: Article

References (21)

1. Garlepp MJ, Leong CC: Biological and immunological aspects of malignant mesothelioma. Eur Respir J 1995;8:643-650.
2. Upham JW, Garlepp MJ, Musk AW, Robinson BW: Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 1995;50:887-893.
3. Filiberti R, Marroni P, Neri M, Ardizzoni A, Betta PG, Cafferata MA, Canessa PA, Puntoni R, Ivaldi GP, Paganuzzi M: Serum PDGF-AB in pleural mesothelioma. Tumour Biol 2005;26:221-226. (Pubitemid 41243222)
4. Versnel MA, Hagemeijer A, Bouts MJ, van der Kwast TH, Hoogsteden HC: Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene 1988;2:601-605.
5. Gerwin BI, Lechner JF, Reddel RR, Roberts AB, Robbins KC, Gabrielson EW, Harris CC: Comparison of production of transforming growth factor-β and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res 1987;47:6180-6184. (Pubitemid 18011059)
6. Van der Meeren A, Seddon MB, Betsholtz CA, Lechner JF, Gerwin BI: Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived growth factor - A chain overexpression. Am J Respir Cell Mol Biol 1993;8:214-221.
7. Alvarez RH, Kantarjian HM, Cortes JE: Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin Proc 2006;81:1241-1257. (Pubitemid 44316290)
8. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, Alitalo K, Eriksson U: PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor. Nat Cell Biol 2001;3:512-516. (Pubitemid 32422089)
9. Fredriksson L, Ehnman M, Fieber C, Eriksson U: Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J Biol Chem 2005;280:26856-26862. (Pubitemid 41040719)
10. Okada A, Yaguchi T, Gotoh A, Nakano T, Nishizaki T: Malignant mesothelioma cell chemotaxis through a PDGF-ββ receptor signaling pathway along a PI3 kinase/PDK1/Akt/Rac1/ROCK axis. Cell Physiol Biochem 2012;29:241-250.
11. Honda M, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T: Mesothelioma cell proliferation through autocrine activation of PDGF-ββ receptor. Cell Physiol Biochem 2012;29:667-674.
12. Niwa H, Yamamura K, Miyazaki J: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-199.
13. Komatsu N, Aoki K, Yamada M, Yukinaga H, Fujita Y, Kamioka Y, Matsuda M: Development of an optimized backbone of FRET biosensors for kinases and GTPases. Mol Biol Cell 2011;22:4647-4656.
14. Rexhepaj R, Rotte A, Pasham V, Gu S, Kempe DS, Lang F: PI3 kinase and PDK1 in the regulation of the electrogenic intestinal dipeptide transport. Cell Physiol Biochem 2010;25:715-722.
15. Kloo B, Nagel D, Pfeifer M, Grau M, Düwel M, Vincendeau M, Dörken B, Lenz P, Lenz G, Krappmann D: Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA 2011;108:272-277.
16. Guo JP, Coppola D, Cheng JQ: IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/ PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 2011;286:37389-37398.
17. Blakely BD, Bye CR, Fernando CV, Horne MK, Macheda ML, Stacker SA, Arenas E, Parish CL: Wnt5a regulates midbrain dopaminergic axon growth and guidance. PLoS One 2011;6:e18373.
18. Bianchi R, Kastrisianaki E, Giambanco I, Donato R: S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J Biol Chem 2011;286:7214-7226.
19. Filice E, Angelone T, De Francesco EM, Pellegrino D, Maggiolini M, Cerra MC: Crucial role of phospholamban phosphorylation and S-nitrosylation in the negative lusitropism induced by 17β-estradiol in the male rat heart. Cell Physiol Biochem 2011;28:41-52.
20. Jayaraman T, Tejero J, Chen BB, Blood AB, Frizzell S, Shapiro C, Tiso M, Hood BL, Wang X, Zhao X, Conrads TP, Mallampalli RK, Gladwin MT: 14-3-3 binding and phosphorylation of neuroglobin during hypoxia modulate six-to-five heme pocket coordination and rate of nitrite reduction to nitric oxide. J Biol Chem 2011;286:42679-42689.
21. Ohori M, Kinoshita T, Okubo M, Sato K, Yamazaki A, Arakawa H, Nishimura S, Inamura N, Nakajima H, Neya M, Miyake H, Fujii T: Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 2005;336:357-363. (Pubitemid 41253441)